BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Castagneto B, Zai S, Mutti L, Lazzaro A, Ridolfi R, Piccolini E, Ardizzoni A, Fumagalli L, Valsuani G, Botta M. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion. Lung Cancer 2001;31:303-10. [DOI: 10.1016/s0169-5002(00)00192-6] [Cited by in Crossref: 57] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Hofmann HS, Wiebe K. [Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion]. Chirurg 2010;81:557-62. [PMID: 20454769 DOI: 10.1007/s00104-010-1926-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
2 Alì G, Boldrini L, Lucchi M, Picchi A, Dell'Omodarme M, Prati MC, Mussi A, Corsi V, Fontanini G. Treatment with interleukin-2 in malignant pleural mesothelioma: immunological and angiogenetic assessment and prognostic impact. Br J Cancer 2009;101:1869-75. [PMID: 19935800 DOI: 10.1038/sj.bjc.6605438] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
3 Bograd AJ, Suzuki K, Vertes E, Colovos C, Morales EA, Sadelain M, Adusumilli PS. Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma. Cancer Immunol Immunother 2011;60:1509-27. [PMID: 21913025 DOI: 10.1007/s00262-011-1103-6] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
4 Calabrò L, Rossi G, Maio M. New horizons from immunotherapy in malignant pleural mesothelioma. J Thorac Dis 2018;10:S322-32. [PMID: 29507802 DOI: 10.21037/jtd.2017.12.88] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
5 Silberhumer GR, Brader P, Wong J, Serganova IS, Gönen M, Gonzalez SJ, Blasberg R, Zamarin D, Fong Y. Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma. Mol Cancer Ther 2010;9:2761-9. [PMID: 20858727 DOI: 10.1158/1535-7163.MCT-10-0090] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
6 Prado-Garcia H, Romero-Garcia S, Aguilar-Cazares D, Meneses-Flores M, Lopez-Gonzalez JS. Tumor-induced CD8+ T-cell dysfunction in lung cancer patients. Clin Dev Immunol 2012;2012:741741. [PMID: 23118782 DOI: 10.1155/2012/741741] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 4.5] [Reference Citation Analysis]
7 Kurai J, Chikumi H, Hashimoto K, Takata M, Sako T, Yamaguchi K, Kinoshita N, Watanabe M, Touge H, Makino H, Igishi T, Hamada H, Yano S, Shimizu E. Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma. Int J Oncol 2012;41:1610-8. [PMID: 22922885 DOI: 10.3892/ijo.2012.1607] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
8 Donnenberg AD, Luketich JD, Dhupar R, Donnenberg VS. Treatment of malignant pleural effusions: the case for localized immunotherapy. J Immunother Cancer 2019;7:110. [PMID: 30999958 DOI: 10.1186/s40425-019-0590-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
9 Alley EW, Katz SI, Cengel KA, Simone CB 2nd. Immunotherapy and radiation therapy for malignant pleural mesothelioma. Transl Lung Cancer Res 2017;6:212-9. [PMID: 28529903 DOI: 10.21037/tlcr.2017.04.01] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
10 Obacz J, Yung H, Shamseddin M, Linnane E, Liu X, Azad AA, Rassl DM, Fairen-Jimenez D, Rintoul RC, Nikolić MZ, Marciniak SJ. Biological basis for novel mesothelioma therapies. Br J Cancer 2021. [PMID: 34226685 DOI: 10.1038/s41416-021-01462-2] [Reference Citation Analysis]
11 Porpodis K, Zarogoulidis P, Boutsikou E, Papaioannou A, Machairiotis N, Tsakiridis K, Katsikogiannis N, Zaric B, Perin B, Huang H, Kougioumtzi I, Spyratos D, Zarogoulidis K. Malignant pleural mesothelioma: current and future perspectives. J Thorac Dis 2013;5 Suppl 4:S397-406. [PMID: 24102013 DOI: 10.3978/j.issn.2072-1439.2013.08.08] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
12 Sigalotti L, Coral S, Altomonte M, Natali L, Gaudino G, Cacciotti P, Libener R, Colizzi F, Vianale G, Martini F, Tognon M, Jungbluth A, Cebon J, Maraskovsky E, Mutti L, Maio M. Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications. Br J Cancer 2002;86:979-82. [PMID: 11953832 DOI: 10.1038/sj.bjc.6600174] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 3.2] [Reference Citation Analysis]
13 Mossman BT, Shukla A, Heintz NH, Verschraegen CF, Thomas A, Hassan R. New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas. Am J Pathol 2013;182:1065-77. [PMID: 23395095 DOI: 10.1016/j.ajpath.2012.12.028] [Cited by in Crossref: 74] [Cited by in F6Publishing: 60] [Article Influence: 8.2] [Reference Citation Analysis]
14 Murthy P, Ekeke CN, Russell KL, Butler SC, Wang Y, Luketich JD, Soloff AC, Dhupar R, Lotze MT. Making cold malignant pleural effusions hot: driving novel immunotherapies. Oncoimmunology 2019;8:e1554969. [PMID: 30906651 DOI: 10.1080/2162402X.2018.1554969] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
15 Den Otter W, Jacobs JJ, Battermann JJ, Hordijk GJ, Krastev Z, Moiseeva EV, Stewart RJ, Ziekman PG, Koten JW. Local therapy of cancer with free IL-2. Cancer Immunol Immunother 2008;57:931-50. [PMID: 18256831 DOI: 10.1007/s00262-008-0455-z] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 3.2] [Reference Citation Analysis]
16 Barsky AR, Cengel KA, Katz SI, Sterman DH, Simone CB 2nd. First-ever Abscopal Effect after Palliative Radiotherapy and Immuno-gene Therapy for Malignant Pleural Mesothelioma. Cureus 2019;11:e4102. [PMID: 31057996 DOI: 10.7759/cureus.4102] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]